Suppr超能文献

经导管再介入治疗先前植入的经导管肺动脉瓣功能障碍的结果。

Outcomes After Transcatheter Reintervention for Dysfunction of a Previously Implanted Transcatheter Pulmonary Valve.

机构信息

St. Louis Children's Hospital, St. Louis, Missouri.

German Heart Institute Berlin, Berlin, Germany.

出版信息

JACC Cardiovasc Interv. 2020 Jul 13;13(13):1529-1540. doi: 10.1016/j.jcin.2020.03.035.

Abstract

OBJECTIVES

The aim of this analysis was to evaluate outcomes following transcatheter reintervention for degenerated transcatheter pulmonary valves (TPVs).

BACKGROUND

TPV replacement (TPVR) with the Melody valve demonstrated sustained relief of right ventricular outflow tract (RVOT) obstruction and pulmonary regurgitation.

METHODS

All patients who underwent TPVR with a Melody valve as part of 3 Medtronic-sponsored prospective multicenter studies were included. Transcatheter reinterventions included balloon dilation of the previously implanted Melody valve, placement of a bare-metal stent within the implanted TPV, or placement of a new TPV in the RVOT (TPV-in-TPV). Indications for reintervention, decisions to reintervene, and the method of reintervention were at physician discretion. All patients provided written informed consent to participate in the trials, and each trial was approved by local or central Institutional Review Boards or ethics committees at participating sites.

RESULTS

A total of 309 patients who underwent TPVR were discharged from the implantation hospitalization with Melody valves in place. Transcatheter reintervention on the TPV was performed in 46 patients. The first transcatheter reintervention consisted of TPV-in-TPV in 28 patients (median 6.9 years [quartile 1 to quartile 3: 5.2 to 7.8 years] after TPVR), simple balloon dilation of the implanted Melody valve in 17 (median 4.9 years [quartile 1 to quartile 3: 4.0 to 6.0 years] after TPVR), and bare-metal stent placement alone in 1 (4.4 years after TPVR). There were no major procedural complications. Overall, 4-year freedom from explant and from any later RVOT reintervention after the first reintervention were 83% and 60%, respectively. Freedom from repeat RVOT reintervention was longer in patients undergoing TPV-in-TPV than balloon dilation (71% vs. 46% at 4 years; p = 0.027).

CONCLUSIONS

TPV-in-TPV can be an effective and durable treatment for Melody valve dysfunction. Although balloon dilation of the Melody valve was also acutely effective at reducing RVOT obstruction, the durability of this therapy was limited in this cohort compared with TPV-in-TPV.

摘要

目的

本分析旨在评估退行性经导管肺动脉瓣(TPV)再介入治疗的结果。

背景

经导管植入 Melody 瓣膜置换术(TPVR)可持续缓解右心室流出道(RVOT)梗阻和肺动脉瓣反流。

方法

所有接受 Medtronic 赞助的 3 项前瞻性多中心研究中植入 Melody 瓣膜的患者均纳入本研究。经导管再介入治疗包括先前植入的 Melody 瓣膜球囊扩张、植入 TPV 内裸金属支架或在 RVOT 内植入新的 TPV(TPV-in-TPV)。再介入治疗的适应证、决定再介入治疗的因素以及再介入治疗的方法均由医生决定。所有患者均签署了参与试验的书面知情同意书,每个试验均获得了参与地点的当地或中央机构审查委员会或伦理委员会的批准。

结果

共有 309 例患者在植入 Melody 瓣膜后出院,这些患者接受了 TPVR。46 例患者对 TPV 进行了经导管再介入治疗。第一次经导管再介入治疗包括 28 例患者的 TPV-in-TPV(TPVR 后中位时间 6.9 年[四分位间距 1 至 3:5.2 至 7.8 年])、17 例患者单纯植入的 Melody 瓣膜球囊扩张(TPVR 后中位时间 4.9 年[四分位间距 1 至 3:4.0 至 6.0 年])和 1 例患者单独植入裸金属支架(TPVR 后 4.4 年)。没有出现重大手术并发症。总体而言,首次再介入治疗后 4 年的瓣膜取出和任何晚期 RVOT 再介入治疗的无事件生存率分别为 83%和 60%。与球囊扩张相比,TPV-in-TPV 患者的重复 RVOT 再介入治疗无事件生存率更长(4 年时分别为 71%和 46%;p=0.027)。

结论

TPV-in-TPV 是治疗 Melody 瓣膜功能障碍的一种有效且持久的方法。虽然 Melody 瓣膜球囊扩张在减轻 RVOT 梗阻方面也具有即刻疗效,但与 TPV-in-TPV 相比,这种治疗在本队列中的耐久性有限。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验